Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2021

Open Access 01-12-2021 | Cytostatic Therapy | Review

Chemoprotective and chemosensitizing effects of apigenin on cancer therapy

Authors: Zahra Nozhat, Shabnam Heydarzadeh, Zahra Memariani, Amirhossein Ahmadi

Published in: Cancer Cell International | Issue 1/2021

Login to get access

Abstract

Background

Therapeutic resistance to radiation and chemotherapy is one of the major obstacles in cancer treatment. Although synthetic radiosensitizers are pragmatic solution to enhance tumor sensitivity, they pose concerns of toxicity and non-specificity. In the last decades, scientists scrutinized novel plant-derived radiosensitizers and chemosensitizers, such as flavones, owing to their substantial physiological effects like low toxicity and non-mutagenic properties on the human cells. The combination therapy with apigenin is potential candidate in cancer therapeutics. This review explicates the combinatorial strategies involving apigenin to overcome drug resistance and boost the anti-cancer properties.

Methods

We selected full-text English papers on international databases like PubMed, Web of Science, Google Scholar, Scopus, and ScienceDirect from 1972 up to 2020. The keywords included in the search were: Apigenin, Chemoprotective, Chemosensitizing, Side Effects, and Molecular Mechanisms.

Results

In this review, we focused on combination therapy, particularly with apigenin augmenting the anti-cancer effects of chemo drugs on tumor cells, reduce their side effects, subdue drug resistance, and protect healthy cells. The reviewed research data implies that these co-therapies exhibited a synergistic effect on various cancer cells, where apigenin sensitized the chemo drug through different pathways including a significant reduction in overexpressed genes, AKT phosphorylation, NFκB, inhibition of Nrf2, overexpression of caspases, up-regulation of p53 and MAPK, compared to the monotherapies. Meanwhile, contrary to the chemo drugs alone, combined treatments significantly induced apoptosis in the treated cells.

Conclusion

Briefly, our analysis proposed that the combination therapies with apigenin could suppress the unwanted toxicity of chemotherapeutic agents. It is believed that these expedient results may pave the path for the development of drugs with a high therapeutic index. Nevertheless, human clinical trials are a prerequisite to consider the potential use of apigenin in the prevention and treatment of various cancers. Conclusively, the clinical trials to comprehend the role of apigenin as a chemoprotective agent are still in infancy.

Graphical Abstract

Literature
1.
Redondo-Blanco S, Fernández J, Gutiérrez-del-Río I, Villar CJ, Lombó F. New insights toward colorectal cancer chemotherapy using natural bioactive compounds. Front Pharmacol. 2017;8:109.PubMedPubMedCentralCrossRef
2.
Ahmadi A, Shadboorestan A, Nabavi S, Setzer W, Nabavi S. The role of hesperidin in cell signal transduction pathway for the prevention or treatment of cancer. Curr Med Chem. 2015;22(30):3462–71.PubMedCrossRef
3.
Shokrzadeh M, Habibi E, Shadboorestan A, Chabra A, Ahmadi A: The protective effects of Origanum vulgare L. extract on genetic damage of cyclophosphamide in mice blood lymphocytes using micronucleus test. Pharm Biomed Res 2020.
4.
Shokrzadeh M, Ahmadi A, Ramezaninejhad S, Shadboorestan A. Hesperidin, a citrus bioflavonoid, ameliorates genotoxicity-induced by diazinon in human blood lymphocytes. Drug research. 2015;65(02):57–60.PubMed
5.
6.
Mahbub A, Le Maitre C, Haywood-Small S, Cross N, Jordan-Mahy N. Dietary polyphenols influence antimetabolite agents: methotrexate, 6-mercaptopurine and 5-fluorouracil in leukemia cell lines. Oncotarget. 2017;8(62):104877.PubMedPubMedCentralCrossRef
7.
Pharmacists ASoH-S: Archived from the original on 20 December 2016. In: Retrieved; 2016.
8.
Suzuki M, Shinohara F, Endo M, Sugazaki M, Echigo S, Rikiishi H. Zebularine suppresses the apoptotic potential of 5-fluorouracil via cAMP/PKA/CREB pathway against human oral squamous cell carcinoma cells. Cancer Chemother Pharmacol. 2009;64(2):223–32.PubMedCrossRef
9.
Shukla S, Gupta S. Apigenin and cancer chemoprevention. In: Bioactive foods in promoting health. Amsterdam: Elsevier; 2010. p. 663–89.CrossRef
10.
Madunić J, Madunić IV, Gajski G, Popić J, Garaj-Vrhovac V. Apigenin: a dietary flavonoid with diverse anticancer properties. Cancer Lett. 2018;413:11–22.PubMedCrossRef
11.
Ali F, Rahul, Naz F, Jyoti S, Siddique YH. Health functionality of apigenin: a review. Int J Food Prop. 2017;20(6):1197–238.CrossRef
12.
Yu S, Yan H, Zhang L, Shan M, Chen P, Ding A, Li SFY. A review on the phytochemistry, pharmacology, and pharmacokinetics of amentoflavone, a naturally-occurring biflavonoid. Molecules. 2017;22(2):299.PubMedCentralCrossRef
13.
Michler H, Laakmann G, Wagner H. Development of an LC-MS method for simultaneous quantitation of amentoflavone and biapigenin, the minor and major biflavones from Hypericum perforatum L., in human plasma and its application to real blood. Phytochem Anal. 2011;22(1):42–50.PubMedCrossRef
14.
Gan L, Ma J, You G, Mai J, Wang Z, Yang R, Xie C, Fei J, Tang L, Zhao J. Glucuronidation and its effect on the bioactivity of amentoflavone, a biflavonoid from Ginkgo biloba leaves. J Pharm Pharmacol. 2020;72(12):1840–53.PubMedCrossRef
15.
Wang M: Interactions between dietary flavonoid apigenin and human gut microbiota in vitro. Rutgers University-School of Graduate Studies; 2018.
16.
Kozlowska M, Laudy AE, Przybył J, Ziarno M, Majewska E. Chemical composition and antibacterial activity of some medicinal plants from Lamiaceae family. Acta Pol Pharm. 2015;72(4):757–67.PubMed
17.
Martins BT, Correia da Silva M, Pinto M, Cidade H, Kijjoa A. Marine natural flavonoids: chemistry and biological activities. Nat Prod Res. 2019;33(22):3260–72.PubMedCrossRef
18.
Telange DR, Patil AT, Pethe AM, Fegade H, Anand S, Dave VS. Formulation and characterization of an apigenin-phospholipid phytosome (APLC) for improved solubility, in vivo bioavailability, and antioxidant potential. Eur J Pharm Sci. 2017;108:36–49.PubMedCrossRef
19.
Qiao L, Sun Y, Chen R, Fu Y, Zhang W, Li X, Chen J, Shen Y, Ye X. Sonochemical effects on 14 flavonoids common in citrus: relation to stability. PloS ONE. 2014;9(2):e87766.PubMedPubMedCentralCrossRef
20.
21.
Wang M, Firrman J, Liu L, Yam K. A review on flavonoid apigenin: Dietary intake, ADME, antimicrobial effects, and interactions with human gut microbiota. BioMed research international. 2019;2019:7010467.PubMedPubMedCentral
22.
Ashrafizadeh M, Bakhoda MR, Bahmanpour Z, Ilkhani K, Zarrabi A, Makvandi P, Khan H, Mazaheri S, Darvish M, Mirzaei H. Apigenin as tumor suppressor in cancers: biotherapeutic activity, nanodelivery, and mechanisms with emphasis on pancreatic cancer. Front Chem. 2020;8:829.PubMedPubMedCentralCrossRef
23.
Zhang S, Yang X, Coburn RA, Morris ME. Structure activity relationships and quantitative structure activity relationships for the flavonoid-mediated inhibition of breast cancer resistance protein. Biochem Pharmacol. 2005;70(4):627–39.PubMedCrossRef
24.
Gandhi YA, Morris ME. Structure–activity relationships and quantitative structure–activity relationships for breast cancer resistance protein (ABCG2). AAPS J. 2009;11(3):541–52.PubMedPubMedCentralCrossRef
25.
Xie Y, Xu K, Linn DE, Yang X, Guo Z, Shimelis H, Nakanishi T, Ross DD, Chen H, Fazli L. The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells. J Biol Chem. 2008;283(6):3349–56.PubMedCrossRef
26.
Ou L, Han S, Ding W, Chen Z, Ye Z, Yang H, Zhang G, Lou Y, Chen J-Z, Yu Y. Design, synthesis and 3D-QSAR study of cytotoxic flavonoid derivatives. Mol Diversity. 2011;15(3):665–75.CrossRef
27.
Singh M, Kaur M, Silakari O. Flavones: an important scaffold for medicinal chemistry. Eur J Med Chem. 2014;84:206–39.PubMedCrossRef
28.
Liu R, Zhang H, Yuan M, Zhou J, Tu Q, Liu J-J, Wang J. Synthesis and biological evaluation of apigenin derivatives as antibacterial and antiproliferative agents. Molecules. 2013;18(9):11496–511.PubMedPubMedCentralCrossRef
29.
Hunyadi A, Martins A, Danko B, Chang F-R, Wu Y-C. Protoflavones: a class of unusual flavonoids as promising novel anticancer agents. Phytochem Rev. 2014;13(1):69–77.CrossRef
30.
Qi Y, Ding Z, Yao Y, Ma D, Ren F, Yang H, Chen A. Novel triazole analogs of apigenin-7-methyl ether exhibit potent antitumor activity against ovarian carcinoma cells via the induction of mitochondrial-mediated apoptosis. Exp Ther Med. 2019;17(3):1670–6.PubMed
31.
Patel D, Shukla S, Gupta S. Apigenin and cancer chemoprevention: progress, potential and promise. Int J Oncol. 2007;30(1):233–45.PubMed
32.
Shoubaky GAE, Abdel-Daim MM, Mansour MH, Salem EA. Isolation and identification of a flavone apigenin from marine red alga Acanthophora spicifera with antinociceptive and anti-Inflammatory activities. J Exp Neurosci. 2016;10:21–9.PubMedPubMedCentralCrossRef
33.
Czeczot H, Tudek B, Kusztelak J, Szymczyk T, Dobrowolska B, Glinkowska G, Malinowski J, Strzelecka H. Isolation and studies of the mutagenic activity in the Ames test of flavonoids naturally occurring in medical herbs. Mutat Res/Genet Toxicol. 1990;240(3):209–16.CrossRef
34.
Birt DF, Walker B, Tibbels MG, Bresnick E. Anti-mutagenesis and anti-promotion by apigenin, robinetin and indole-3-carbinol. Carcinogenesis. 1986;7(6):959–63.PubMedCrossRef
35.
Banerjee K, Banerjee S, Das S, Mandal M. Probing the potential of apigenin liposomes in enhancing bacterial membrane perturbation and integrity loss. J Colloid Interface Sci. 2015;453:48–59.CrossRefPubMed
36.
37.
Tsuji P, Walle T. Cytotoxic effects of the dietary flavones chrysin and apigenin in a normal trout liver cell line. Chem Biol Interact. 2008;171(1):37–44.PubMedCrossRef
38.
Meyer H, Bolarinwa A, Wolfram G, Linseisen J. Bioavailability of apigenin from apiin-rich parsley in humans. Ann Nutr Metab. 2006;50(3):167–72.PubMedCrossRef
39.
Nielsen S, Young J, Daneshvar B, Lauridsen S, Knuthsen P, Sandström B, Dragsted LO. Effect of parsley (Petroselinum crispum) intake on urinary apigenin excretion, blood antioxidant enzymes and biomarkers for oxidative stress in human subjects. Br J Nutr. 1999;81(6):447–55.PubMedCrossRef
40.
Gradolatto A, Basly J-P, Berges R, Teyssier C, Chagnon M-C, Siess M-H, Canivenc-Lavier M-C. Pharmacokinetics and metabolism of apigenin in female and male rats after a single oral administration. Drug Metab Dispos. 2005;33(1):49–54.PubMedCrossRef
41.
Griffiths L, Smith G. Metabolism of apigenin and related compounds in the rat. Metabolite formation in vivo and by the intestinal microflora in vitro. Biochem J. 1972;128(4):901–11.PubMedPubMedCentralCrossRef
42.
Pforte H, Hempel J, Jacobasch G. Distribution pattern of a flavonoid extract in the gastrointestinal lumen and wall of rats. Food Nahrung. 1999;43(3):205–8.CrossRef
43.
Ding S, Zhang Z, Song J, Cheng X, Jiang J, Jia X. Enhanced bioavailability of apigenin via preparation of a carbon nanopowder solid dispersion. Int J Nanomed. 2014;9:2327.CrossRef
44.
Tang D, Chen K, Huang L, Li J. Pharmacokinetic properties and drug interactions of apigenin, a natural flavone. Expert Opin Drug Metab Toxicol. 2017;13(3):323–30.PubMedCrossRef
45.
Chen J, Lin H, Hu M. Metabolism of flavonoids via enteric recycling: role of intestinal disposition. J Pharmacol Exp Ther. 2003;304(3):1228–35.PubMedCrossRef
46.
Yasumatsu R, Nakashima T, Uryu H, Masuda M, Hirakawa N, Shiratsuchi H, Tomita K, Fukushima M, Komune S. The role of dihydropyrimidine dehydrogenase expression in resistance to 5-fluorouracil in head and neck squamous cell carcinoma cells. Oral Oncol. 2009;45(2):141–7.PubMedCrossRef
47.
Choi EJ, Kim G-H. 5-Fluorouracil combined with apigenin enhances anticancer activity through induction of apoptosis in human breast cancer MDA-MB-453 cells. Oncol Rep. 2009;22(6):1533–7.PubMedCrossRef
48.
Way T-D, Kao M-C, Lin J-K. Degradation of HER2/neu by apigenin induces apoptosis through cytochrome c release and caspase-3 activation in HER2/neu-overexpressing breast cancer cells. FEBS Lett. 2005;579(1):145–52.PubMedCrossRef
49.
Nozhat Z, Hedayati M. PI3K/AKT pathway and its mediators in thyroid carcinomas. Mol Diagn Ther. 2016;20(1):13–26.PubMedCrossRef
50.
Lee W-J, Chen W-K, Wang C-J, Lin W-L, Tseng T-H. Apigenin inhibits HGF-promoted invasive growth and metastasis involving blocking PI3K/Akt pathway and β4 integrin function in MDA-MB-231 breast cancer cells. Toxicol Appl Pharmacol. 2008;226(2):178–91.PubMedCrossRef
51.
Chan L-P, Chou T-H, Ding H-Y, Chen P-R, Chiang F-Y, Kuo P-L, Liang C-H. Apigenin induces apoptosis via tumor necrosis factor receptor-and Bcl-2-mediated pathway and enhances susceptibility of head and neck squamous cell carcinoma to 5-fluorouracil and cisplatin. Biochimica et Biophysica Acta. 2012;1820(7):1081–91.PubMedCrossRef
52.
Johnson JL, de Mejia EG. Interactions between dietary flavonoids apigenin or luteolin and chemotherapeutic drugs to potentiate anti-proliferative effect on human pancreatic cancer cells, in vitro. Food Chem Toxicol. 2013;60:83–91.PubMedCrossRef
53.
Hu XY, Liang JY, Guo XJ, Liu L, Guo YB. 5-Fluorouracil combined with apigenin enhances anticancer activity through mitochondrial membrane potential (ΔΨm)-mediated apoptosis in hepatocellular carcinoma. Clin Exp Pharmacol Physiol. 2015;42(2):146–53.PubMedCrossRef
54.
Gaballah HH, Gaber RA, Mohamed DA. Apigenin potentiates the antitumor activity of 5-FU on solid Ehrlich carcinoma: crosstalk between apoptotic and JNK-mediated autophagic cell death platforms. Toxicol Appl Pharmacol. 2017;316:27–35.PubMedCrossRef
55.
56.
Jung YY, Lee YK, Koo JS. The potential of Beclin 1 as a therapeutic target for the treatment of breast cancer. Expert Opin Ther Targets. 2016;20(2):167–78.PubMedCrossRef
57.
Yang C, Pan Y. Fluorouracil induces autophagy-related gastric carcinoma cell death through Beclin-1 upregulation by miR-30 suppression. Tumor Biology. 2016;37(12):15489–94.CrossRef
58.
Goodwin C, Rossanese O, Olejniczak E, Fesik S. Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer. Cell Death Differ. 2015;22(12):2098–106.PubMedPubMedCentralCrossRef
59.
García-Foncillas J, Sunakawa Y, Aderka D, Wainberg Z, Ronga P, Witzler P, Stintzing S. Distinguishing features of cetuximab and panitumumab in colorectal cancer and other solid tumors. Front Oncol. 2019;9:849.PubMedPubMedCentralCrossRef
60.
Ocvirk J, Cencelj S. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer. J Eur Acad Dermatol Venereol. 2010;24(4):453–9.PubMedCrossRef
61.
Boeckx C, de Beeck KO, Wouters A, Deschoolmeester V, Limame R, Zwaenepoel K, Specenier P, Pauwels P, Vermorken JB, Peeters M. Overcoming cetuximab resistance in HNSCC: the role of AURKB and DUSP proteins. Cancer Lett. 2014;354(2):365–77.PubMedCrossRef
62.
Ameyar M, Wisniewska M, Weitzman J. A role for AP-1 in apoptosis: the case for and against. Biochimie. 2003;85(8):747–52.PubMedCrossRef
63.
Boeckx C, Blockx L, de Beeck KO, Limame R, Van Camp G, Peeters M, Vermorken JB, Specenier P, Wouters A, Baay M. Establishment and characterization of cetuximab resistant head and neck squamous cell carcinoma cell lines: focus on the contribution of the AP-1 transcription factor. Am J Cancer Res. 2015;5(6):1921.PubMedPubMedCentral
64.
Tewari D, Nabavi SF, Nabavi SM, Sureda A, Farooqi AA, Atanasov AG, Vacca RA, Sethi G, Bishayee A. Targeting activator protein 1 signaling pathway by bioactive natural agents: possible therapeutic strategy for cancer prevention and intervention. Pharmacol Res. 2018;128:366–75.PubMedCrossRef
65.
Briggs JJ, Haugen MH, Johansen HT, Riker AI, Abrahamson M, Fodstad Ø, Mælandsmo GM, Solberg R. Cystatin E/M suppresses legumain activity and invasion of human melanoma. BMC Cancer. 2010;10(1):17.PubMedPubMedCentralCrossRef
66.
Baines K, Renaud S. Transcription factors that regulate trophoblast development and function. In: Progress in molecular biology and translational science, vol. 145. Amsterdam: Elsevier; 2017. p. 39–88.
67.
Zhang X, Wu J, Luo S, Lechler T, Zhang JY. FRA1 promotes squamous cell carcinoma growth and metastasis through distinct AKT and c-Jun dependent mechanisms. Oncotarget. 2016;7(23):34371.PubMedPubMedCentralCrossRef
68.
Pavón MA, Arroyo-Solera I, Céspedes MV, Casanova I, León X, Mangues R. uPA/uPAR and SERPINE1 in head and neck cancer: role in tumor resistance, metastasis, prognosis and therapy. Oncotarget. 2016;7(35):57351.PubMedPubMedCentralCrossRef
69.
Vechio AMCD, Giudice FS, Sperandio FF, Mantesso A, Pinto Junior DS. Vimentin expression and the influence of Matrigel in cell lines of head and neck squamous cell carcinoma. Brazil Oral Res. 2011;25(3):235–40.CrossRef
70.
Hu W-J, Liu J, Zhong L-K, Wang J. Apigenin enhances the antitumor effects of cetuximab in nasopharyngeal carcinoma by inhibiting EGFR signaling. Biomed Pharmacother. 2018;102:681–8.PubMedCrossRef
71.
Ma BB, Poon TC, To K, Zee B, Mo FK, Chan CM, Ho S, Teo PM, Johnson PJ, Chan AT. Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma—a prospective study. Head Neck. 2003;25(10):864–72.PubMedCrossRef
72.
Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol. 2002;20(18):1s–13s.PubMed
73.
Barabas K, Milner R, Lurie D, Adin C. Cisplatin: a review of toxicities and therapeutic applications. Vet Compar Oncol. 2008;6(1):1–18.CrossRef
74.
75.
76.
Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 2008;73(9):994–1007.PubMedCrossRef
77.
Gupta S, Afaq F, Mukhtar H. Selective growth-inhibitory, cell-cycle deregulatory and apoptotic response of apigenin in normal versus human prostate carcinoma cells. Biochem Biophys Res Commun. 2001;287(4):914–20.PubMedCrossRef
78.
Ju SM, Kang JG, Bae JS, Pae HO, Lyu YS, Jeon BH. The flavonoid apigenin ameliorates cisplatin-induced nephrotoxicity through reduction of p53 activation and promotion of PI3K/Akt pathway in human renal proximal tubular epithelial cells. Evid Based Complementary Altern Med. 2015;2015:186436.CrossRef
79.
Liu R, Ji P, Liu B, Qiao H, Wang X, Zhou L, Deng T, Ba Y. Apigenin enhances the cisplatin cytotoxic effect through p53-modulated apoptosis. Oncol Lett. 2017;13(2):1024–30.PubMedCrossRef
80.
He X, Li C, Wei Z, Wang J, Kou J, Liu W, Shi M, Yang Z, Fu Y. Protective role of apigenin in cisplatin-induced renal injury. Eur J Pharmacol. 2016;789:215–21.PubMedCrossRef
81.
Lu Y, Cederbaum AI. Enhancement by pyrazole of lipopolysaccharide-induced liver injury in mice: Role of cytochrome P450 2E1 and 2A5. Hepatology. 2006;44(1):263–74.PubMedCrossRef
82.
Hassan SM, Khalaf MM, Sadek SA, Abo-Youssef AM. Protective effects of apigenin and myricetin against cisplatin-induced nephrotoxicity in mice. Pharm Biol. 2017;55(1):766–74.PubMedPubMedCentralCrossRef
83.
Caltagirone S, Rossi C, Poggi A, Ranelletti FO, Natali PG, Brunetti M, Aiello FB, Piantelli M. Flavonoids apigenin and quercetin inhibit melanoma growth and metastatic potential. Int J Cancer. 2000;87(4):595–600.PubMedCrossRef
84.
Xu Y-Y, Wu T-T, Zhou S-H, Bao Y-Y, Wang Q-Y, Fan J, Huang Y-P. Apigenin suppresses GLUT-1 and p-AKT expression to enhance the chemosensitivity to cisplatin of laryngeal carcinoma Hep-2 cells: an in vitro study. Int J Clin Exp Pathol. 2014;7(7):3938.PubMedPubMedCentral
85.
Aziz NA, Froemming GRA, Kadir SHSA, Ibahim MJ: Apigenin increases cisplatin inhibitory effects on the telomerase activity of triple negative breast cancer cells. Jurnal Teknologi 2018, 80(1).
86.
Erdogan S, Turkekul K, Serttas R, Erdogan Z. The natural flavonoid apigenin sensitizes human CD44+ prostate cancer stem cells to cisplatin therapy. Biomed Pharmacother. 2017;88:210–7.PubMedCrossRef
87.
Qi Y, Ding Z, Yao Y, Ren F, Yin M, Yang S, Chen A. Apigenin induces apoptosis and counteracts cisplatin-induced chemoresistance via Mcl-1 in ovarian cancer cells. Exp Ther Med. 2020;20(2):1329–36.PubMedPubMedCentralCrossRef
88.
Kelly GL, Strasser A. Toward targeting antiapoptotic MCL-1 for cancer therapy. Annu Rev Cancer Biol. 2020;4:299–313.CrossRef
89.
Li Q, Li L, Zhao X, Cheng Z, Ma J. Apigenin induces apoptosis and reverses the drug resistance of ovarian cancer cells. Int J Clin Exp Med. 2020;13(3):1987–94.
90.
Larson RA. Etiology and management of therapy-related myeloid leukemia. Hematology. 2007;2007(1):453–9.CrossRef
91.
Bokulić A, Garaj-Vrhovac V, Brajša K, Ðurić K, Glojnarić I, Šitum K. The effect of apigenin on cyclophosphamide and doxorubicin genotoxicity in vitro and in vivo. J Environ Sci Health Part A. 2011;46(5):526–33.CrossRef
92.
Mahbub AA, Le Maitre CL, Haywood-Small S, Cross NA, Jordan-Mahy N. Polyphenols enhance the activity of alkylating agents in leukaemia cell lines. Oncotarget. 2019;10(44):4570.PubMedPubMedCentralCrossRef
93.
Arora I, Sharma M, Tollefsbol TO. Combinatorial epigenetics impact of polyphenols and phytochemicals in cancer prevention and therapy. Int J Mol Sci. 2019;20(18):4567.PubMedCentralCrossRef
94.
Gao A-M, Ke Z-P, Wang J-N, Yang J-Y, Chen S-Y, Chen H. Apigenin sensitizes doxorubicin-resistant hepatocellular carcinoma BEL-7402/ADM cells to doxorubicin via inhibiting PI3K/Akt/Nrf2 pathway. Carcinogenesis. 2013;34(8):1806–14.PubMedCrossRef
95.
Gao A-M, Zhang X-Y, Ke Z-P. Apigenin sensitizes BEL-7402/ADM cells to doxorubicin through inhibiting miR-101/Nrf2 pathway. Oncotarget. 2017;8(47):82085.PubMedPubMedCentralCrossRef
96.
Gao A-M, Zhang X-Y, Hu J-N, Ke Z-P. Apigenin sensitizes hepatocellular carcinoma cells to doxorubic through regulating miR-520b/ATG7 axis. Chem Biol Interact. 2018;280:45–50.PubMedCrossRef
97.
Shen K, Cui D, Sun L, Lu Y, Han M, Liu J. Inhibition of IGF-IR increases chemosensitivity in human colorectal cancer cells through MRP-2 promoter suppression. J Cell Biochem. 2012;113(6):2086–97.PubMedCrossRef
98.
Zhang P, Singh A, Yegnasubramanian S, Esopi D, Kombairaju P, Bodas M, Wu H, Bova SG, Biswal S. Loss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth. Mol Cancer Ther. 2010;9(2):336–46.PubMedPubMedCentralCrossRef
99.
Leung CH, Caldarone CA, Guan R, Wen X-Y, Ailenberg M, Kapus A, Szaszi K, Rotstein OD. Nuclear factor (erythroid-derived 2)-like 2 regulates the hepatoprotective effects of remote ischemic conditioning in hemorrhagic shock. Antioxid Redox Signal. 2019;30(14):1760–73.PubMedCrossRef
100.
Korga A, Ostrowska M, Jozefczyk A, Iwan M, Wojcik R, Zgorka G, Herbet M, Vilarrubla GG, Dudka J. Apigenin and hesperidin augment the toxic effect of doxorubicin against HepG2 cells. BMC Pharmacol Toxicol. 2019;20(1):1–13.CrossRef
101.
Zhu Y, Liu C, Nadiminty N, Lou W, Tummala R, Evans CP, Gao AC. Inhibition of ABCB1 expression overcomes acquired docetaxel resistance in prostate cancer. Mol Cancer Ther. 2013;12(9):1829–36.PubMedPubMedCentralCrossRef
102.
Vendelbo J, Olesen RH, Lauridsen JK, Rungby J, Kleinman J, Hyde T, Larsen A. Increasing BMI is associated with reduced expression of P-glycoprotein (ABCB1 gene) in the human brain with a stronger association in African Americans than Caucasians. Pharmacogenomics J. 2018;18(1):121–6.PubMedCrossRef
103.
Angelini A, Di CI, Castellani M, Conti P, Cuccurullo F. Modulation of multidrug resistance p-glycoprotein activity by flavonoids and honokiol in human doxorubicin-resistant sarcoma cells (MES-SA/DX-5): implications for natural sedatives as chemosensitizing agents in cancer therapy. J Biol Regul Homeost Agents. 2010;24(2):197–205.PubMed
104.
Seo HS, Ku JM, Choi HS, Woo JK, Lee BH, Kim DS, Song HJ, Jang BH, Shin YC, Ko SG. Apigenin overcomes drug resistance by blocking the signal transducer and activator of transcription 3 signaling in breast cancer cells. Oncol Rep. 2017;38(2):715–24.PubMedPubMedCentralCrossRef
105.
Mahbub A, Le Maitre C, Haywood-Small S, Cross N, Jordan-Mahy N. Polyphenols act synergistically with doxorubicin and etoposide in leukaemia cell lines. Cell Death Discov. 2015;1(1):1–12.CrossRef
106.
Yu W, Sun H, Zha W, Cui W, Xu L, Min Q, Wu J: Apigenin attenuates adriamycin-induced cardiomyocyte apoptosis via the PI3K/AKT/mTOR pathway. Evidence-Based Complementary and Alternative Medicine 2017, 2017.
107.
Zare MFR, Rakhshan K, Aboutaleb N, Nikbakht F, Naderi N, Bakhshesh M, Azizi Y. Apigenin attenuates doxorubicin induced cardiotoxicity via reducing oxidative stress and apoptosis in male rats. Life Sci. 2019;232:116623.PubMedCrossRef
108.
Ittiudomrak T, Puthong S, Roytrakul S, Chanchao C. α-mangostin and apigenin induced cell cycle arrest and programmed cell death in SKOV-3 ovarian cancer cells. Toxicol Res. 2019;35(2):167–79.PubMedPubMedCentralCrossRef
109.
Jain A, Kwong LN, Javle M. Genomic profiling of biliary tract cancers and implications for clinical practice. Curr Treat Options Oncol. 2016;17(11):58.PubMedCrossRef
110.
Toschi L, Finocchiaro G, Bartolini S, Gioia V, Cappuzzo F. Role of gemcitabine in cancer therapy. Future Oncol. 2005;1(1):7–17.PubMedCrossRef
111.
Lee SH, Ryu JK, Lee K-Y, Woo SM, Park JK, Yoo JW, Kim Y-T, Yoon YB. Enhanced anti-tumor effect of combination therapy with gemcitabine and apigenin in pancreatic cancer. Cancer Lett. 2008;259(1):39–49.PubMedCrossRef
112.
Strouch MJ, Milam BM, Melstrom LG, McGill JJ, Salabat MR, Ujiki MB, Ding X-Z, Bentrem DJ. The flavonoid apigenin potentiates the growth inhibitory effects of gemcitabine and abrogates gemcitabine resistance in human pancreatic cancer cells. Pancreas. 2009;38(4):409–15.PubMedCrossRef
113.
Giri MK. Aboveground forest biomass modeling using remote sensing and FIA Data in Tennessee. USA: Tennessee State University; 2018.
114.
Choi S-J, Choi J-S. The promotive effects of antioxidative apigenin on the bioavailability of paclitaxel for oral delivery in rats. Biomol Ther. 2010;18(4):469–76.CrossRef
115.
Kumar KK, Priyanka L, Gnananath K, Babu PR, Sujatha S. Pharmacokinetic drug interactions between apigenin, rutin and paclitaxel mediated by P-glycoprotein in rats. Eur J Drug Metab Pharmacokinet. 2015;40(3):267–76.PubMedCrossRef
116.
Xu Y, Xin Y, Diao Y, Lu C, Fu J, Luo L, Yin Z. Synergistic effects of apigenin and paclitaxel on apoptosis of cancer cells. PloS ONE. 2011;6(12):e29169.PubMedPubMedCentralCrossRef
117.
Li K, Li M, Luo Z, Mao Y, Yu Y, He Y, Zhou J, Fei Y, Pei Y, Cai K. Overcoming the hypoxia-induced drug resistance in liver tumor by the concurrent use of apigenin and paclitaxel. Biochem Biophys Res Commun. 2020;526(2):321–7.PubMedCrossRef
118.
Pal MK, Jaiswar SP, Dwivedi A, Goyal S, Dwivedi VN, Pathak AK, Kumar V, Sankhwar PL, Ray RS. Synergistic effect of graphene oxide coated nanotised apigenin with paclitaxel (GO-NA/PTX): a ROS dependent mitochondrial mediated apoptosis in ovarian cancer. Anti-Cancer Agents Med Chem. 2017;17(12):1721–32.
119.
Lang L. FDA approves sorafenib for patients with inoperable liver cancer. Gastroenterology. 2008;134(2):379.PubMed
120.
Şirin N, Elmas L, Seçme M, Dodurga Y. Investigation of possible effects of apigenin, sorafenib and combined applications on apoptosis and cell cycle in hepatocellular cancer cells. Gene. 2020;737:144428.PubMedCrossRef
121.
Zhou J, Li W, Ming J, Yang W, Lu L, Zhang Q, Ruan S, Huang T. High expression of TRAF4 predicts poor prognosis in tamoxifen-treated breast cancer and promotes tamoxifen resistance. Anticancer Drugs. 2020;31(6):558–66.PubMedCrossRef
122.
Vanitha Samuel PN: Modifying role of apigenin in angiogenesis and anti-oxidant status in experimentally induced breast cancer in rats. International Journal of Basic & Clinical Pharmacology 2015, 4(6).
123.
Long X, Fan M, Bigsby RM, Nephew KP. Apigenin inhibits antiestrogen-resistant breast cancer cell growth through estrogen receptor-α-dependent and estrogen receptor-α-independent mechanisms. Mol Cancer Ther. 2008;7(7):2096–108.PubMedPubMedCentralCrossRef
124.
Saha RP, Singh MK, Samanta S, Bhakta S, Mandal S, Bhattacharya M, Sharma AR, Lee S-S, Chakraborty C. Repurposing drugs, ongoing vaccine and new therapeutic development initiatives against COVID-19. Front Pharmacol. 2020;11:1258.PubMedPubMedCentralCrossRef
125.
Huang S, Yu M, Shi N, Zhou Y, Li F, Li X, Huang X, Jin J. Apigenin and Abivertinib, a novel BTK inhibitor synergize to inhibit diffuse large B-cell lymphoma in vivo and vitro. J Cancer. 2020;11(8):2123.PubMedPubMedCentralCrossRef
126.
127.
Oishi M, Iizumi Y, Taniguchi T, Goi W, Miki T, Sakai T. Apigenin sensitizes prostate cancer cells to Apo2L/TRAIL by targeting adenine nucleotide translocase-2. PLoS ONE. 2013;8(2):e55922.PubMedPubMedCentralCrossRef
128.
Zhang W, Wei Y, Yu D, Xu J, Peng J. Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non–small cell lung cancer: a meta-analysis. BMC Cancer. 2018;18(1):780.PubMedPubMedCentralCrossRef
129.
Chen Z, Tian D, Liao X, Zhang Y, Xiao J, Chen W, Liu Q, Chen Y, Li D, Zhu L. Apigenin combined with gefitinib blocks autophagy flux and induces apoptotic cell death through inhibition of HIF-1α, c-Myc, p-EGFR, and glucose metabolism in EGFR L858R+ T790M-mutated H1975 cells. Front Pharmacol. 2019;10:260.PubMedPubMedCentralCrossRef
130.
Yang P-M, Chou C-J, Tseng S-H, Hung C-F. Bioinformatics and in vitro experimental analyses identify the selective therapeutic potential of interferon gamma and apigenin against cervical squamous cell carcinoma and adenocarcinoma. Oncotarget. 2017;8(28):46145.PubMedPubMedCentralCrossRef
131.
Kanarek N, Keys HR, Cantor JR, Lewis CA, Chan SH, Kunchok T, Abu-Remaileh M, Freinkman E, Schweitzer LD, Sabatini DM. Histidine catabolism is a major determinant of methotrexate sensitivity. Nature. 2018;559(7715):632–6.PubMedPubMedCentralCrossRef
132.
Ruela-de-Sousa R, Fuhler GM, Blom N, Ferreira CV, Aoyama H, Peppelenbosch MP. Cytotoxicity of apigenin on leukemia cell lines: implications for prevention and therapy. Cell Death Dis. 2010;1(1):e19–e19.PubMedPubMedCentralCrossRef
133.
Nozhat Z, Mohammadi-Yeganeh S, Azizi F, Zarkesh M, Hedayati M. Effects of metformin on the PI3K/AKT/FOXO1 pathway in anaplastic thyroid Cancer cell lines. DARU J Pharm Sci. 2018;26(2):93–103.CrossRef
134.
135.
Warkad MS, Kim C-H, Kang B-G, Park S-H, Jung J-S, Feng J-H, Inci G, Kim S-C, Suh H-W, Lim SS. Metformin-induced ROS upregulation as amplified by apigenin causes profound anticancer activity while sparing normal cells. Sci Rep. 2021;11(1):1–13.CrossRef
136.
Ashrafizadeh M, Bakhoda MR, Bahmanpour Z, Ilkhani K, Zarrabi A, Makvandi P, Khan H, Mazaheri S, Darvish M, Mirzaei H. Apigenin as tumor suppressor in cancers: biotherapeutic activity, nanodelivery, and mechanisms with emphasis on pancreatic cancer. Front Chem. 2020;8:829.PubMedPubMedCentralCrossRef
137.
Javed Z, Sadia H, Iqbal MJ, Shamas S, Malik K, Ahmed R, Raza S, Butnariu M, Cruz-Martins N, Sharifi-Rad J. Apigenin role as cell-signaling pathways modulator: implications in cancer prevention and treatment. Cancer Cell Int. 2021;21(1):1–11.CrossRef
138.
Sen K, Banerjee S, Mandal M. Dual drug loaded liposome bearing apigenin and 5-Fluorouracil for synergistic therapeutic efficacy in colorectal cancer. Colloids Surf, B. 2019;180:9–22.CrossRef
139.
140.
Heydarzadeh S, Moshtaghie AA, Daneshpoor M, Hedayati M. Regulators of glucose uptake in thyroid cancer cell lines. Cell Commun Signal. 2020;18:1–16.CrossRef
141.
Metadata
Title
Chemoprotective and chemosensitizing effects of apigenin on cancer therapy
Authors
Zahra Nozhat
Shabnam Heydarzadeh
Zahra Memariani
Amirhossein Ahmadi
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2021
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-021-02282-3

Other articles of this Issue 1/2021

Cancer Cell International 1/2021 Go to the issue

Primary Research

Comprehensive analysis of pyroptosis regulators and tumor immune microenvironment in clear cell renal cell carcinoma

Primary research

Construction of a long noncoding RNA-based competing endogenous RNA network and prognostic signatures of left- and right-side colon cancer

Primary Research

Eribulin activity in soft tissue sarcoma monolayer and three-dimensional cell line models: could the combination with other drugs improve its antitumoral effect?

Primary Research

Attenuated expression of SNF5 facilitates progression of bladder cancer via STAT3 activation

Primary research

The inhibitory effect of silencing CDCA3 on migration and proliferation in bladder urothelial carcinoma

Primary research

Circular RNA hsa_circ_0002483 promotes growth and invasion of lung adenocarcinoma by sponging miR-125a-3p
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits